MMR vaccine for adults is mostly about records, not boosters. New measles data explain who needs another dose and how the shot and the titer are billed.
On November 17 the Pan American Health Organization announced that its regional verification commission had determined endemic measles transmission was re-established in the United States, Bolivia and Mexico, and that all three countries had lost elimination status. The criterion is narrow: the same virus genotype and lineage circulating without interruption for 12 months or more. The Americas region reported 58,213 confirmed cases and 82 deaths as of November 13, against 12,806 cases in the same stretch of 2025.
CIDRAP News, published by the University of Minnesota, followed on November 19 with a harder read on what the designation means, quoting three former CDC leaders and warning that falling MMR coverage has opened the door for mumps, rubella and whooping cough as well. For an adult holding a 2027 plan card, none of that answers the question that actually costs money: is a dose needed, or is a record needed, and who pays for which.
What losing elimination status changes for adults
The CDC’s latest case update, covering confirmed cases as of November 12, counted 5,412 U.S. cases reported by 47 jurisdictions, including 18 among international visitors. Ninety-six percent of cases were associated with outbreaks, and CDC counted 43 new outbreaks this year. The 2026 total already dwarfs the 2,289 confirmed cases reported for all of 2025. The same update showed kindergarten MMR coverage had declined from 95.2% in the 2019-2020 school year to 92.4% in 2025-2026, leaving roughly 280,000 kindergartners without the protection the two-dose series is meant to provide. The death count is less settled: CIDRAP reports at least 11 this year, while CDC's case page lists a lower confirmed figure and notes that the number will change as the agency and the Council of State and Territorial Epidemiologists settle a standard definition for measles deaths.
Here is what did not happen on November 17. Elimination status is a population-level measure, and losing it did not rewrite the adult schedule or change a single coverage rule. Nobody's plan changed, no vaccine became newly free or newly billable, and no insurer added a requirement. What did change is the odds that an outbreak notice reaches a specific adult, and with it the odds that a health department recommends an extra dose for people in a particular group, including some who already have one documented dose. That is a local recommendation layered on top of the routine schedule, and it is the one place where an adult who is technically up to date can be told to get another shot.
Who needs another dose
For most adults born in 1957 or later, one documented MMR dose given at age 12 months or older meets the routine adult standard. CDC does not recommend a catch-up second dose for every adult. A second dose is recommended for specific higher-risk groups, including students at post-high-school institutions, healthcare personnel, international travelers, close contacts of people who are immunocompromised, and adults with HIV who are not severely immunocompromised. Groups identified as being at increased risk during an outbreak may also be advised to receive two doses.
A key distinction: a person may need proof of immunity rather than another shot. A verbal recollection of vaccination is not a substitute for written documentation under CDC guidance. If records cannot be located, another dose is generally safe for someone who may already be immune. CDC does not recommend antibody testing after vaccination.
The CDC’s adult measles vaccination guidance lists four acceptable forms of evidence of immunity: written documentation of adequate vaccination, laboratory evidence of immunity, laboratory confirmation of measles disease, or birth before 1957. The pre-1957 rule is presumptive evidence, not a record of a specific infection.
There are two historical exceptions to check. Adults vaccinated before 1968 with inactivated, or killed, measles vaccine, or with a vaccine of unknown type, should be revaccinated. By contrast, people with documentation that they received live measles vaccine in the 1960s do not need revaccination. People who are pregnant or have certain immune conditions should ask a healthcare professional whether MMR is appropriate before getting a dose.
Where to look for the record
Vaccination records may be held by a state immunization information system, the original healthcare provider, or the state health department. CDC does not keep individual vaccination records. State registry access differs, but where an online portal is available, a request through the portal may be faster than arranging a provider visit.

Search for childhood and adult vaccine records, including records from a former provider or pharmacy. If a registry search does not return a record, contact the provider or state health department. A missing record does not establish that a person was never vaccinated; it means the available documentation has not been found.
The titer question and how it may be billed
A measles titer, sometimes called an MMR titer when several antibodies are tested, is a blood test that looks for laboratory evidence of immunity. It is not the same benefit as receiving a preventive vaccine. A titer may be useful when a record is unavailable, but CDC does not recommend checking antibodies after vaccination.
Marketplace plans must cover recommended preventive services, including immunizations, without copay or coinsurance when delivered by an in-network provider. HealthCare.gov’s preventive care guidance also says coverage details can vary and should be confirmed with the plan.
The billing difference matters. An MMR dose is generally handled as a preventive service. A measles antibody titer is a diagnostic laboratory test and may be subject to the deductible and coinsurance. In practical terms, proving immunity with a test may cost more out of pocket than receiving a preventive dose. This is an interpretation of how preventive-service rules and diagnostic lab benefits interact, not a guarantee for every plan. Confirm the test’s coverage, network status, and likely member cost with the insurer before testing.

When confirming vaccine coverage, ask whether both the vaccine and administration fee are processed under the preventive benefit. Also ask whether a separate office visit will be billed. An appointment that includes a separate evaluation or diagnostic service may have different cost sharing from the vaccine itself.
For a dose received in January, the preventive vaccine benefit generally remains separate from the plan-year deductible when the ACA coverage conditions are met. However, a separately billed diagnostic service or office visit may apply to the new plan year’s deductible after January 1. This is an interpretation of preventive coverage and plan-year billing, not a CDC conclusion. Plan terms control; check the Summary of Benefits and Coverage for cost-sharing details.
The 72-hour window after exposure
After a known measles exposure, contact a healthcare professional or local health department promptly. MMR vaccine given within 72 hours of first exposure may provide some protection or make illness milder. For people at high risk of severe disease, immune globulin may be given within six days. The two forms of post-exposure prophylaxis should not be given at the same time.
Immune globulin is treatment after exposure, not a routine preventive vaccine. It is generally billed through medical benefits rather than the preventive vaccine benefit and may involve cost sharing. Coverage depends on the plan and circumstances.
A checklist before the next outbreak notice
Use this sequence to review adult measles immunity and coverage:
- Search the state immunization registry, original provider, and state health department for written records.
- Check the birth-year rule. Birth before 1957 is presumptive evidence of immunity, with special considerations for healthcare personnel.
- Confirm whether a documented dose was given at age 12 months or later.
- Check whether a higher-risk category applies, such as healthcare work, college, international travel, living with an immunocompromised person, or HIV without severe immunocompromise.
- Check current state or local outbreak guidance. An outbreak recommendation for an additional dose is different from the routine adult schedule.
- Ask the insurer whether the MMR vaccine and administration are in network and covered as preventive care. Ask whether any separate visit charge applies.
- Know whom to contact if exposed. The 72-hour window for MMR and six-day window for immune globulin are time-sensitive.
Questions for an agent or benefits administrator
Ask the insurer or benefits administrator four things before booking anything. Is the vaccine provider in network? Is the administration fee included under the preventive benefit, or billed separately? Would an office visit be charged on top of the shot? And if a titer is ordered, is it processed as diagnostic laboratory testing, meaning the deductible and coinsurance apply?
An agent or broker can walk through the network and benefit terms, and can check a plan's Summary of Benefits and Coverage with you before you commit to an appointment. Questions about medical eligibility, exposure, or whether a dose is indicated belong to a healthcare professional or the local health department, not an agent.
Limitations
Federal recommendations, state health department guidance, and plan terms may change or differ in application. CDC case data are preliminary, updated on a schedule, and may lag state reports by about a week. This article is general information, not medical or benefits advice. Confirm current recommendations with a healthcare professional and coverage details with the plan.